Final Coverage-With-Evidence-Development Guidance Delayed By CMS Staff Cuts
This article was originally published in The Gray Sheet
Executive Summary
The CMS coverage and analysis group has had to divert its attention from finishing a CED guidance to finalizing proposed changes to the process for awarding Medicare coverage for IDE trials, primarily due to staff cuts, says Louis Jacques, who heads the group.
You may also be interested in...
Louis Jacques On Coverage, Evidence And IDEs
Former CMS coverage director Louis Jacques talks about the strong future ahead he envisions for the Medicare coverage-with-evidence-development program and new coverage policies that will be implemented for investigational device exemption trials.
Louis Jacques On Coverage, Evidence And IDEs
In the first part of a two-part Q&A, just-departed CMS coverage director Louis Jacques talks about the strong future ahead he envisions for the Medicare coverage-with-evidence-development program and new coverage policies that will be implemented for investigational device exemption trials.
People Briefs: Louis Jacques To Leave CMS; FDA, MHRA Appointments
Louis Jacques, who directs CMS’ coverage office, will leave the agency at the end of the month. FDA appoints acting deputy chief scientist. The U.K. Medicines and Healthcare products Regulatory Agency names clinical director of medical devices. More people briefs.